Table 4.
Trends of drug-resistant Mycobacterium tuberculosis clinical isolates against four first-line anti-TB drugs at a major hospital in Guizhou Province of China, 2008–2015
| New cases
|
Previously treated cases
|
Total cases
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| 2008–20103 (n=172) | 2011–20124 (n=57) | 2013–2015 (n=319) | 2008–20103 (n=91) | 2011–20124 (n=35) | 2013–2015 (n=143) | 2008–20103 (n=263) | 2011–20124 (n=92) | 2013–2015 (n=462) | |
|
| |||||||||
| Resistance to first-line anti-TB drugs (%) | |||||||||
|
| |||||||||
| Rifampicin | 12.2 | 19.3 | 4.4 | 56.0 | 25.7 | 44.1 | 27.4 | 21.7 | 16.7 |
| Isoniazid | 14.5 | 14.0 | 8.8 | 59.3 | 37.1 | 47.6 | 30.0 | 22.8 | 20.8 |
| Ethambutol | 7.6 | 1.8 | 4.1 | 41.8 | 14.3 | 32.2 | 19.4 | 6.5 | 12.8 |
| Streptomycin | 32.0 | 22.8 | 8.5 | 50.6 | 22.9 | 36.4 | 38.4 | 22.8 | 17.1 |
| MDR-TBa | 8.1 | 10.5 | 3.4 | 45.1 | 22.9 | 38.5 | 20.9 | 15.2 | 14.3 |
Note:
a
MDR is defined as resistance to rifampicin and isoniazid.
Abbreviations: MDR-TB, multidrug-resistant tuberculosis; TB, tuberculosis.